借助ETF及联接基金把握创新药投资机遇

Group 1 - The 2025 ASCO annual meeting showcased outstanding clinical data from several domestic innovative drug companies, highlighting advancements in antibody-drug conjugates (ADCs), bispecific antibodies, and new-generation small molecules [1] - The increasing number of presentations by Chinese experts at international platforms indicates that Chinese pharmaceutical companies are rapidly advancing in innovative research and development [1] - The innovative drug sector is poised for a "golden era" of investment, with potential for reshaping global market perceptions [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the Hong Kong Stock Connect Innovative Drug Index, allowing investors to easily invest in leading companies within the Hong Kong innovative drug industry [2] - The implementation of the 18A listing rule in the Hong Kong market has attracted many quality domestic innovative drug companies to list and raise funds, contributing to the positive earnings trend of these companies [2] - The valuation of the Hong Kong innovative drug index is considered attractive due to high profitability from the underlying companies, especially with the upcoming 2024 annual report disclosures [2]